Each patient becomes their own stem cell donor
In a convergence of molecular biology and human longing, three University of California campuses have received federal clearance to attempt the first direct repair of the genetic misspelling that causes sickle cell disease — not in a laboratory dish, but inside the living cells of nine patients. Using CRISPR tools delivered without viral carriers, researchers will extract a patient's own blood stem cells, correct the single faulty letter in the beta-globin gene, and return them home. The trial, launching this summer in Oakland and Los Angeles, carries the weight of a disease that has shaped and shortened lives across generations, falling with particular force on Black communities worldwide. It is, at its core, an attempt to rewrite a sentence that was never supposed to be written that way.
- A disease caused by a single miswritten letter in the genetic code has resisted a widely accessible cure for decades, leaving roughly 100,000 Americans and millions worldwide in cycles of pain, organ damage, and shortened lives.
- The only proven treatment — a bone marrow transplant — demands a matched donor that researchers compare to finding a needle in a haystack, placing it out of reach for most patients.
- A three-campus UC collaboration will now attempt something never tried in a human: using electrical pulses to open blood stem cells and allow CRISPR machinery to slip inside and correct the mutation directly, bypassing the risks of viral delivery entirely.
- Researchers believe correcting as few as 20 percent of a patient's stem cells may be enough to tip the biological balance, allowing repaired cells to outcompete sickle cells and restore normal oxygen transport.
- Nine patients — six adults and three adolescents — will enter the four-year trial this summer, carrying with them the hopes of a global patient population and the ambitions of scientists who have spent six years preparing for this moment.
Three University of California campuses have received FDA approval to launch the first clinical trial using CRISPR to directly correct the genetic mutation behind sickle cell disease in a patient's own cells. The trial, beginning this summer in Oakland and Los Angeles, will enroll nine patients — six adults and three adolescents — all living with severe forms of the disease.
Sickle cell disease is caused by a single miswritten letter in the genetic code, one that instructs the body to produce malformed hemoglobin. The resulting crescent-shaped red blood cells clog vessels, starving tissues of oxygen and causing chronic pain, organ damage, and shortened lives. The disease affects around 100,000 Americans, with a disproportionate burden on Black communities, and millions more worldwide.
The current standard of care — a bone marrow transplant from a matched donor — works but is risky and rarely accessible. The new trial takes a different path: blood stem cells are extracted from each patient and transported to UCLA's manufacturing lab, where electrical pulses temporarily open the cell membranes, allowing CRISPR-Cas9 molecules to enter, locate the sickle mutation, and correct it. The repaired cells are then returned to the patient. This non-viral delivery method avoids the complications and costs associated with previous gene therapy approaches.
The collaboration draws on the distinct strengths of UC San Francisco, UC Berkeley, and UCLA. Nobel laureate Jennifer Doudna, who co-invented CRISPR and first proposed its use against sickle cell disease in 2014, helped establish the scientific foundation. Donald Kohn at UCLA leads manufacturing and clinical operations, while UCSF pediatrics professor Mark Walters serves as principal investigator. The trial represents six years of pre-clinical groundwork.
Researchers believe correcting just 20 percent of a patient's stem cells may be sufficient to produce meaningful clinical benefit, as repaired cells would gradually outcompete the native sickle cells. Beyond sickle cell disease, the model itself carries broader implications — each patient becomes their own donor, eliminating compatibility barriers and potentially serving as a template for treating other genetic blood disorders. Doudna has emphasized that the consortium's goal is a cure that is accessible globally, not only to those in wealthy nations.
Three University of California campuses have won federal approval to attempt something that has never been tried in a human patient: using CRISPR gene-editing tools to reach into a person's own blood cells, find the single genetic misspelling that causes sickle cell disease, and fix it. The trial, which begins this summer in Oakland and Los Angeles, will enroll nine patients—six adults and three adolescents—all living with severe sickle cell disease. If it works, it could reshape how the disease is treated.
Sickle cell disease is caused by a mutation so small it amounts to a single letter changed in the genetic code. That tiny error tells the body to make hemoglobin that folds wrong, creating red blood cells shaped like sickles instead of discs. These deformed cells jam in blood vessels, starving tissues of oxygen and causing pain, organ damage, and a shortened lifespan. The disease affects roughly 100,000 Americans, with a disproportionate burden falling on Black communities. Worldwide, millions live with it.
The standard treatment today is a bone marrow transplant from a matched donor—a procedure that works but carries real risks and requires finding a compatible donor, a process researchers describe as searching for a needle in a haystack. The new trial takes a different path. Doctors will extract blood stem cells from each patient and send them to UCLA's manufacturing laboratory. There, the cells will be exposed to electrical pulses that temporarily open their membranes, allowing CRISPR-Cas9 molecules to slip inside and travel to the cell nucleus. Once there, the molecular machinery will locate the sickle mutation and correct it. The edited cells will then be returned to the patient.
This approach is fundamentally different from previous gene therapies for sickle cell disease, which either tried to reactivate fetal hemoglobin or used viruses as delivery vehicles to insert new genes. Using electroporation—the electrical pulse method—to deliver CRISPR avoids the complications and costs associated with viral vectors. It is also the first time researchers will attempt to directly repair the faulty beta-globin gene in a patient's own cells using non-viral CRISPR delivery.
The trial is a collaboration between UC San Francisco, UC Berkeley, and UCLA, drawing on distinct expertise from each institution. Jennifer Doudna, the Nobel Prize-winning scientist at Berkeley who helped invent CRISPR, founded the Innovative Genomics Institute and first proposed a CRISPR-based cure for sickle cell disease in 2014. Donald Kohn at UCLA, who has already developed gene therapies for other blood disorders, will oversee the manufacturing and clinical work. Mark Walters, a pediatrics professor at UCSF and principal investigator, will lead the trial itself. The four-year study represents six years of pre-clinical work.
Walters and his team believe that correcting the mutation in just 20 percent of a patient's blood stem cells should be enough to produce a strong clinical benefit. The corrected cells, once reintroduced, would out-compete the native sickle cells and restore normal oxygen transport. If successful in these nine patients, the approach could prevent the irreversible complications that accumulate over a sickle cell patient's lifetime—organ failure, stroke, chronic pain.
What makes this trial significant beyond sickle cell disease is its model. Kohn notes that gene therapy and gene editing allow each patient to become their own stem cell donor, eliminating the need to find a match and making the treatment theoretically safer than transplantation from another person. If this works, it could become a template for treating other genetic blood disorders. Doudna emphasized that the trial emerges from a consortium of nonprofit academic institutions motivated by a long-term vision: a cure that is accessible and affordable globally, not just for wealthy patients in wealthy countries.
The FDA has already cleared the trial to proceed. The real test begins this summer, when the first patients arrive at clinics in Oakland and Los Angeles to have their blood drawn, their cells edited, and their hope restored.
Notable Quotes
This therapy has the potential to transform sickle cell disease care by producing an accessible, curative treatment that is safer than the current therapy of stem cell transplant from a healthy bone marrow donor.— Mark Walters, principal investigator, UCSF Benioff Children's Hospital Oakland
Gene therapy and gene editing allow each patient to serve as their own stem cell donor. In theory, these approaches should be much safer than a transplant from another person and could become universally available.— Donald Kohn, UCLA
The Hearth Conversation Another angle on the story
Why does it matter that this uses electroporation instead of a virus to deliver CRISPR?
Viruses are efficient at getting into cells, but they're expensive, they can trigger immune reactions, and they carry their own risks. Electroporation is simpler—you just zap the cells with electricity and the CRISPR molecules slip through the temporary openings. It's cheaper, it's safer, and it's never been done this way in a human patient before.
So they're extracting cells, editing them outside the body, and putting them back. Why not just edit the cells while they're still inside the patient?
Because you can't control what happens inside a living body the way you can in a lab. Out here, you can monitor every step, measure how many cells got corrected, make sure nothing went wrong before you return them. It's more work, but it's also more precise.
The trial only needs to correct 20 percent of the genes. That seems low.
It is, and that's actually the elegant part. The corrected cells are healthier than the sickle cells. Once they're back in circulation, they naturally out-compete the damaged ones. You don't need to fix everything—just enough to tip the balance.
Who benefits most from this if it works?
Immediately, these nine patients. But the real impact is on the communities hit hardest by sickle cell disease—Black Americans, who carry the mutation at much higher rates. And if this becomes a template, it opens doors for other genetic blood disorders. That's what the researchers are thinking about.
What's the risk here?
It's early. Nine patients is a small group. We don't know yet if the corrected cells will stay corrected long-term, or if there are side effects that only show up months or years later. That's why it's called a clinical trial, not a cure.
Why did it take until 2021 to try this?
CRISPR itself is only about a decade old as a tool. The safety work, the manufacturing process, the regulatory conversations with the FDA—all of that takes years. Doudna proposed this in 2014, and it took six years of pre-clinical work just to get here.